Sept. 30, 2022 Price forecast | 2 weeks: -3.97% | 1 month: -4.07% | 3 months: -9.03%


HROW stock forecast

Our latest prediction for Harrow Health Inc's stock price was made on the Sept. 30, 2022 when the stock price was at 12.07$.

In the short term (2weeks), HROW's stock price should underperform the market by -3.97%. During that period the price should oscillate between -18.15% and +6.83%.

In the medium term (3months), HROW's stock price should underperform the market by -9.03%. During that period the price should oscillate between -36.55% and +24.08%.

Create a solid portfolio with HROW

Add HROW to your portfolio and optimize it!


About Harrow Health Inc

Harrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical-stage drug candidates being developed by Surface and Melt. Supported by dedicated employees, Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first.

At the moment the company generates 7M USD in revenues.

On its last earning announcement, the company reported a loss of -0.62$ per share.

The book value per share is 0.60$

Harrow Health Inc website


Three months stock forecastSept. 30, 2022


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
7M 795.49% -1M -21.63% -24M -0.62 - - 27M 0.60 - - -